About oritavanci n as diphosphat
Glycopeptide antibiotic
Used for
- Treats acute bacterial skin and skin-structure infections caused by susceptible bacteria, including MRSA.
Usual adult dose
Single intravenous dose of 1,200 mg, infused over 3 hours.
Usual dose in children
For patients aged 3 months and older: single intravenous dose based on weight, infused over 3 hours; maximum 1,200 mg.
Common side effects
- Nausea
- Headache
- Vomiting
- Infusion-related reactions, including flushing or itching
Important warnings
- Can interfere with certain blood-clotting test results for up to 120 hours.
- Avoid intravenous unfractionated heparin for 120 hours after treatment.
- Infuse over 3 hours; faster infusion can cause reactions.
- Use only for infections proven or strongly suspected to be bacterial.
Pregnancy
Available information is insufficient to determine risks during pregnancy; use requires clinical assessment.
Breastfeeding
It is unknown whether oritavancin passes into breast milk; clinical assessment is needed.
Interactions
- May increase warfarin effects; monitor clotting after treatment.
- Can affect coagulation tests, including activated partial thromboplastin time, for up to 120 hours.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.